Showing results (61-70 of 80) with videos related to
Sort By:
Pageof 8
The New England Journal of Medicine|February 11, 2016
Caplacizumab for Acquired Thrombotic Thrombocytopenic PurpuraFlora Peyvandi, Marie Scully, Johanna A Kremer Hovinga, et al.The New England Journal of Medicine|January 10, 2019
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic PurpuraMarie Scully, Spero R Cataland, Flora Peyvandi, et al.Research and Practice in Thrombosis and Haemostasis|October 18, 2024
Comorbidity and adverse events in acquired hemophilia A: data from the GTH-AHA-EMI studyChristian Herbert Burgmann, Ulrich J Sachs, Karolin Trautmann-Grill, et al.Journal of Thrombosis and Haemostasis : JTH|January 9, 2022
Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpuraLucas Kühne, Jessica Kaufeld, Linus A Völker, et al.Journal of Thrombosis and Haemostasis : JTH|September 22, 2022
Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES studyMarie Scully, Javier de la Rubia, Katerina Pavenski, et al.Blood Advances|August 12, 2025
Sustained Survival Benefit of Emicizumab and Postponed Immunosuppression in Acquired Hemophilia AInga M Schimansky, Christiane Dobbelstein, Robert Klamroth, et al.Leukemia & Lymphoma|January 14, 2016
Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphomaPhilipp Wohlfarth, Alexander Carlström, Thomas Staudinger, et al.Neoplasia (New York, N.Y.)|November 3, 2021
Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosisDaniela Berger, Karin Bauer, Christoph Kornauth, et al.Haematologica|November 13, 2025
Thrombin generation to predict breakthrough bleeding in patients with acquired hemophilia A under emicizumab prophylaxisFabius J Pelzer, Ella I Ertekin, Olga Oleshko, et al.The Lancet. Haematology|October 20, 2023
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 studyAndreas Tiede, Christina Hart, Paul Knöbl, et al.Pageof 8